Biogen reports Q3 EPS $4.08, consensus $3.79

Reports Q3 revenue $2.47B, consensus $2.43B. President and Chief Executive Officer Christopher Viehbacher said: “In the third quarter Biogen (BIIB) made continued progress toward our goal of returning to sustainable growth. We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline. This quarter we had several significant positive developments in key areas of our late-stage pipeline which we believe underscore the potential value for both patients and shareholders. Importantly, the positive results for dapirolizumab pegol, as well as recent presentations of felzartamab data in IgAN, bolster our efforts to develop an industry-leading pipeline in immunology, where we are building upon data insights and increasing our capabilities to prepare for potential future launches.”